Default: Current Cancer Drug Targets

ISSN: 1568-0096

Journal Home

Journal Guideline

Current Cancer Drug Targets Q2 Unclaimed

Bentham Science Publishers B.V. United Arab Emirates
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Current Cancer Drug Targets is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 99. It has an SJR impact factor of 0,687 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,687.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Current Cancer Drug Targets

0,687

SJR Impact factor

99

H Index

69

Total Docs (Last Year)

228

Total Docs (3 years)

5875

Total Refs

723

Total Cites (3 years)

219

Citable Docs (3 years)

2.95

Cites/Doc (2 years)

85.14

Ref/Doc

Comments

No comments ... Be the first to comment!



Best articles by citations

miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents

View more

Molecular Targeting of Liposomal Nano-Particles to Lymphatic System

View more

Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer

View more

Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy

View more

PI-3-Kinase Inhibitors in Colorectal Cancer

View more

Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment

View more

HSV-1 Viral Oncolysis and Molecular Imaging with PET

View more

Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer

View more

The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review

View more

Targeting STEAP1 Protein in Human Cancer: Current Trends and Future Challenges

View more

Editorial (Thematic Issue: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy)

View more

AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1

View more
SHOW MORE ARTICLES

Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer

View more

Author Index To Volume 6

View more

Editorial [ Hot Topic: Oncolytic Virus Therapy (Guest Editor: Hideki Kasuya) ]

View more

Meet Our Editorial Board Member:

View more

Melatonin as a Selective Estrogen Enzyme Modulator

View more

Clinical Development of 17-Allylamino, 17-Demethoxygeldanamycin

View more

Silica Nanoparticles as Promising Drug/Gene Delivery Carriers and Fluorescent Nano-Probes: Recent Advances

View more

Sam68 Promotes the Progression of Human Breast Cancer through inducing Activation of EphA3

View more

Identification of the ZAK-MKK4-JNK-TGFβ Signaling Pathway as a Molecular Target for Novel Synthetic Iminoquinone Anticancer Compound BA-TPQ

View more

Anatomic Site-Related Expression of Cancer-Associated Molecules in Ovarian Carcinoma

View more

Nanotherapy Targeting the Tumor Microenvironment

View more

Costimulation, Coinhibition and Cancer

View more

FAQS